tbuckley/cabot-search huggingface dataset:
SAT0455 Baseline and Persistent Knee Symptoms Are Independent Predictors of Structural Progression of Knee Osteoarthritis
Authors: J. Martel-Pelletier, A.J. Teichtahl, F.M. Cicuttini, Y. Wang, F. Abram, J.-P. Pelletier
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Although studies have predominantly focused on whether disease progression predicts symptoms in knee osteoarthritis (OA), there is very little data examining whether the presence of knee symptoms may be an independent predictor of the structural progression of knee OA. <h3>Objectives</h3> To complement and extend previous studies, we examined whether baseline and persistent knee symptoms predicted accelerated cartilage volume loss, incident and progressive radiographic OA (ROA) and total knee replacement (TKR). <h3>Methods</h3> Participants from the Osteoarthritis Initiative were grouped according to the absence (Kellgren-Lawrence [KL] grade ≤1, n=2120) or presence (KL ≥2, n=2249) of baseline ROA. Clinical symptoms (pain, stiffness and function) were assessed at baseline using Western Ontario and McMaster University Osteoarthritis Index (WOMAC). Cartilage volume in the medial and lateral compartments was assessed by magnetic resonance imaging (MRI) at baseline and 48 months. Associations with incident and progressive ROA were assessed at 48 months and TKR at 72 months. <h3>Results</h3> Higher levels of baseline and persistent knee symptoms predicted greater annual percentage of cartilage loss in the medial (all p&lt;0.05) and lateral (all p≤0.03) compartment in people both with and without ROA. Greater baseline and persistent knee symptoms were associated with incidence (OR range 1.02 to 1.29, all p≤0.005) and progression (OR range 1.01 to 1.22, all p≤0.01) of ROA, as well as TKR (OR range 1.03 to 1.35; all p&lt;0.001). <h3>Conclusions</h3> Greater baseline and persistent knee symptoms predicted accelerated cartilage loss, incident and progressive ROA and TKR. Although a major focus in OA research has been the link between structural disease and symptom progression, data from this study demonstrate that symptoms are important independent predictors of disease progression. This suggests that targeting symptoms may be important for preserving joint structure. <h3>Disclosure of Interest</h3> J. Martel-Pelletier Shareholder of: ArthroLab Inc., A. Teichtahl: None declared, F. Cicuttini: None declared, Y. Wang: None declared, F. Abram Employee of: ArthroLab Inc., J.-P. Pelletier Shareholder of: ArthroLab Inc.
THU0575 Tocilizumab Is Significantly Steroid-Sparing Compared with Methotrexate in Polymyalgia Rheumatica: A Multicenter Retrospective Study (NTMC-KEIO PMR Study)
Authors: K. Izumi, O. Murata, M. Ushikubo, H. Ito, K. Akiya, Y. Kaneko, H. Oshima, T. Takeuchi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> We have recently reported the effectiveness of tocilizumab (TCZ) against polymyalgia rheumatica (PMR) in a case series. <h3>Objectives</h3> Here, we aimed to investigate the efficacy of TCZ on the steroid-sparing effect in the treatment of PMR as compared with methotrexate (MTX). <h3>Methods</h3> We retrospectively studied all consecutive patients with PMR, diagnosed according to Bird9s criteria and/or the 2012 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) provisional classification criteria, who had been treated at Keio University Hospital or National Tokyo Medical Center for at least 6 months between November 2005 and November 2015. The patients were divided into 3 groups based on the treatment at the last follow-up: prednisolone (PSL) monotherapy (PSL group), MTX+PSL (MTX group) and TCZ+PSL combination therapies (TCZ group). We evaluated the PSL dose in each therapy group at the last follow-up. TCZ was infused at 8 mg/kg every 4 weeks. 3 patients treated with both MTX and TCZ were excluded. <h3>Results</h3> Of 220 patients, 173 were in the PSL group, 32 in the MTX group, and 15 in the TCZ group. No difference was found in the proportion of women, mean age and the initial PSL dose among the PSL, MTX, and TCZ group (female, 72.8%, 78.1%, 73.3%; mean age, 73.1, 72.5, 74.1 years; initial PSL dose, 14.2, 16.2, 16.1 mg/day, respectively). The disease duration at the last follow-up in the PSL, MTX, and TCZ groups was 80.5, 60.4, and 43.3 months, respectively. The duration of MTX/TCZ use in combination with PSL was not different between the MTX and TCZ groups (30.2 vs 22.3 months, P=0.56). The PSL dose at the last follow-up in the TCZ group was much lower than the PSL and MTX groups (0.3, 3.2, 4.0 mg/day, P&lt;0.0001). The patients in the TCZ group could discontinued PSL more frequently than the PSL and MTX groups (80.0%, 28.3%, 18.8%, P&lt;0.0001 between the PSL and TCZ groups; P&lt;0.0001 between the MTX and TCZ groups). The reduction in daily PSL dose at 6 months from the initiation of MTX/TCZ was much higher in the TCZ group than in the MTX group (-74.7% vs -29.6%, P&lt;0.0001). Two patients discontinued MTX treatment because of adverse events (pneumonia and nausea) while none discontinued TCZ treatment. <h3>Conclusions</h3> TCZ is significantly steroid-sparing compared with MTX in the treatment of PMR. TCZ but not MTX may serve as an effective therapeutic option for patients who require quick reduction or discontinuation of PSL. <h3>References</h3> Izumi K, Kuda H, Ushikubo M, Kuwana M, Takeuchi T, Oshima H. Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open. 2015;1(1):e000162. <h3>Disclosure of Interest</h3> None declared
Low Absolute Lymphocyte Count (ALC) at Diagnosis Is An IPSS-Independent Predictor of Poorer Survival in Myelodysplastic Syndromes (MDS)
Authors: Nisha L Jacobs, Shernan G Holtan, Luis F Porrata, Svetomir N Markovic, Ayalew Tefferi, David P. Steensma
Journal: Blood (2008)
No Mutations of SF3B1, U2AF1, and SRSF2 spliceosomal Gene but Polymorphisms Associated with the Worse Prognosis in Multiple Myeloma
Authors: Min-Gu Kang, Hye-Ran Kim, Jun Hyung Lee, Thashma Pemmanda Ganapathy, Seung-Hyeon Yang, Moinul Hoque, Ra-Young Park, Seung Jung Kee, Soo Hyun Kim, Jong-Hee Shin, Soon-Pal Suh, Myung-Geun Shin
Journal: Blood (2015)
AB0600 High Prevalence of Reduced Bone Mineral Density and Undertreatment of Osteoporosis in Patients with Systemic Sclerosis: Table 1.
Authors: M.J. Spanjer, A.E. Voskuyl, W.F. Lems, I.E.M. Bultink
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic sclerosis is a systemic inflammatory rheumatic disease with a very low prevalence, that has been associated with an increased risk of low bone mineral density (BMD)<sup>1</sup>, but data on risk factors associated with bone loss in systemic sclerosis are scarce. <h3>Objectives</h3> The objective of this study was to investigate the prevalence of and risk factors for low BMD in patients with systemic sclerosis. <h3>Methods</h3> Demographic and clinical data of 61 patients with systemic sclerosis were collected. BMD measurements of the lumbar spine, total hip and femoral neck were performed using DXA. Osteoporosis was defined as a T score less than -2.5 SD and osteopenia as a T-score between -1.0 and -2.5 SD, according to WHO definitions. Systemic sclerosis disease severity was defined by the Rodnan skin score and by the Medsger disease severity score<sup>2</sup>. Multiple linear regression analyses was used to assess factors associated with BMD. <h3>Results</h3> Patients were on average 56.7±12.4 years old and 72% were female of whom 77% postmenopausal. BMD measurements revealed osteopenia or osteoporosis in at least one measurement site in 67% of the patients, of whom 30% had osteoporosis. Low body mass index and postmenopausal state were significantly associated with low BMD in all skeletal sites. No significant associations were found between age, Rodnan skin score, Medsger disease severity score, glucocorticoid treatment and BMD. Of the 30% of patients who had an indication for anti-osteoporosis treatment, 91% did not receive anti-osteoporosis medication. <h3>Conclusions</h3> The results of this cross-sectional study demonstrate a high frequency of osteoporosis or osteopenia in 67% of our patients with systemic sclerosis and low body mass index and postmenopausal state were identified as the most important risk factors. No relationship between disease severity and BMD was found, which could be related to the sample size, although it can be argued that low BMI is, at least partly, a marker of disease severity. This study also shows a high frequency (91%) of undertreatment of osteoporosis in this patient group. These results underline the importance of monitoring and treatment of low BMD in systemic sclerosis. <h3>References</h3> Omair MA, et al. Low bone density in systemic sclerosis: a systematic review. J Rheumatol 2013;40:1881–90. Medsger TA jr, et al. Assessment of disease severity and prognosis. Clin Exp Rheumatol 2003;21:S42–6. <h3>Disclosure of Interest</h3> None declared
THU0354 Thrombocytopenia in Patients with Antiphospholipid Antibodies: A Paradoxical Thrombotic Risk Factor
Authors: R. Hisada, M. Kato, E. Sugawara, K. Ohmura, I. Nakagawa, K. Oku, T. Bohgaki, O. Amengual, T. Horita, S. Yasuda, T. Atsumi
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Thrombocytopenia is a non-criteria manifestation of antiphospholipid syndrome (APS). Antiphospholipid antibodies (aPL) have been shown to activate platelet through multiple mechanisms. In patients with idiopathic/immune thrombocytopenia, aPL have been shown to increase the risk of thrombosis. Conversely, it remains unclear whether thrombocytopenia increases the risk of thrombosis in patients who have aPL. <h3>Objectives</h3> To evaluate the relationship between thrombocytopenia and thrombosis in patients who have aPL. <h3>Methods</h3> A single center retrospective study comprising 670 consecutive patients who underwent testing for aPL including lupus anticoagulant, anticardiolipin antibodies (IgG and M), anti-β2-glycoprotein I antibodies (IgG and M), and phosphatidylserine-dependent antiprothrombin antibodies (IgG and M) between January 2004 and December 2006. Excluded were patients who had been followed-up for ≤1 year. <h3>Results</h3> Of 524 patients included in this study, 187 had systemic lupus erythematosus, 70 rheumatoid arthritis, and 33 primary APS. At least one of aPL was positive in 241 patients. The prevalence of thrombocytopenia was not different in aPL positive and negative patients (24% vs 18%, p=0.11). In aPL positive group, patients with thrombocytopenia experienced arterial thrombosis (46% vs. 17%, p&lt;0.001), venous thrombosis (27% vs. 7%, p&lt;0.001), and recurrent thrombosis (10% vs. 2%, p=0.006) more frequently than patients without thrombocytopenia. Lupus anticoagulant (56% vs. 35%, p=0.006) and phosphatidylserine-dependent antiprothrombin antibodies (57% vs 34%, p=0.001) were more prevalent in patients with thrombocytopenia than in those without. Higher aPL score (Otomo K, et al. Arthritis Rheum 2012), were detected higher (p=0.001) in patients with thrombocytopenia than in those without. In aPL negative group, conversely, patients with and without thrombocytopenia similarly experienced thrombosis (23% vs 16%, p=0.23). <h3>Conclusions</h3> Our data indicate that thrombocytopenia is associated with the risk of thrombosis in aPL positive patients providing new insight into the pathophysiology of aPL mediated platelet activation. <h3>Disclosure of Interest</h3> None declared
A Serum Biomarker Panel Composed of C-Reactive Protein and Albumin Could Predict the Transplant-Related Complications and the Outcomes of Allogeneic Hematopoietic Cell Transplantation
Authors: Kazutaka Ozeki, Yukiyasu Ozawa, Naomi Kawashima, Yusuke Yamaga, Yoshitaka Adachi, Koji Umemura, Shoichiro Okazaki, Akio Kohno, Koichi Miyamura, Yoshihisa Morishita
Journal: Blood (2015)
PWE-022 Diagnosis and Management of Latent Tuberculosis and Its Treatment in IBD Patients Receiving Biologic Therapy
Authors: P Wolfson, AA Thi, S Bouri, L Owen, A Abbara, L John, RN Davidson, AL Hart
Journal: Gut (2016)

<h3>Introduction</h3> Anti-TNF therapies for inflammatory bowel disease (IBD) can lead to a five fold increase of tuberculosis (TB) reactivation in patients with latent TB infection (LTBI). Current European Crohn’s and Colits Organisation recommends LTBI screening with Interferon Gamma Release Assay (IGRA) according to local prevalence, national recommendations and preferred in BCG immunised individuals. In this study, we determine the proportion of LTBI in our cohort of IBD patients treated with biologics and any complications of treatment, particularly drug-induced liver injury (DILI). <h3>Methods</h3> All patients with IBD who were treated with biologics between March 2007 and November 2015 were identified from the high cost funding database held at the Pharmacy of St Mark’s Hospital. Case notes and electronic records were retrospectively reviewed to identify records of LTBI screening. The following were excluded from the analysis: those who were treated for active TB and those who did not receive treatment either for latent or active TB. Of note, at this site, in July 2013, an IGRA testing replaced the Mantoux on our screening algorithm. DILI was defined as deranged liver function tests with no other identifiable cause. <h3>Results</h3> Seven hundred and thirty-two IBD patients were screened for TB prior to starting a biologic. 31 patients (4.2%) were identified as having LTBI and had prophylactic treatment for TB (19 with single agent isoniazid; 12 dual agent isoniazid and rifampicin). Of these 31 patients, 22 went on to have anti-TNF treatment with a median delay of 86 days (range = 7–336 days). Of the 31 that went on to have treatment for latent TB, 3% (n = 1) had side effects, dizziness which was not severe to be stopped the LTBI treatment and non had DILI. <h3>Conclusion</h3> Rate of LTBI in this population receiving biologics for IBD was 4%; all identified patients were treated and none experienced significant side effects. The median time to starting biologics after screening was 86 days, which may represent a significant delay in starting biologics for the IBD patients; this could have detrimental effects to their IBD related morbidity. There remains the risk of false negative IGRA results in an immunosupressed patient and, as such, place of birth and likely previous exposure should be taken into account. <h3>Reference</h3> 1 Rahier J, Moutschen M, Van Gompel A, Van Ranst M, Louis E, Segaert S, <i>et al</i>. Vaccinations in patients with immune-mediated inflammatory diseases. <i>Rheumatology (Oxford)</i> 2010;<b>49</b>:1815–1827. <h3>Disclosure of Interest</h3> None Declared
Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation
Authors: Se young Han, Pavan Kumar Bhamidipati, Khoan Vu, John F Dipersio, Feng Gao, Iskra Pusic, Geoffrey L. Uy, Peter Westervelt, Ravi Vij, Mark A. Schroeder, Camille N. Abboud, Keith Stockerl-Goldstein, Amanda F. Cashen, Todd A Fehniger, Rizwan Romee
Journal: Blood (2015)
THU0578 Factors Associated with Early Diagnosis of Familial Mediterranean Fever
Authors: M.E. Tezcan, M. Avcı, N.B. Kalkan, A. Giousouf, N. Dasdemir Vardi, N. Akbal, E. Sevinc, S. Celik, M. Sargin
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Familial Mediterranean fever (FMF) is characterized by recurrent attacks of polyserositis. Delay in treatment may lead to recurrent attacks and amyloidosis. <h3>Objectives</h3> In this study, we aimed to evaluate clinical features of patients diagnosed early and compared to those diagnosed late <h3>Methods</h3> We enrolled 143 FMF patients over the age of 18 who met Tel-Hashomer Criterias into the study. Demographic features of the patients, duration of education, smoking habits, family history of FMF disease and amyloidosis,; features, duration and frequency of FMF attacks; age at first FMF attack; age at first admittance to a specialist, time between first FMF attack to first admittance to a specialist and which medical specialities patients admitted for their symptoms were recorded with face to face survey method. Else, MEFV gene mutations of the patients, time between first admittance to a specialist to diagnosis, clinical decision and judgement of the specialists at the time of diagnosis were obtained from hospital9s medical recording system. Early diagnosis was defined as within three years after the first symptom. <h3>Results</h3> Mean diagnostic delay was 12.03±10.43 years. Age at first FMF attack (p=0.020), time between first FMF attack to first admittance to a specialist (p=0.003) and first admittance to a specialist after year 2000 (p=0.001) were found statistically important related with early diagnosis in a regression model. MEFV mutation was the only method that had an influence on the decision making of doctors in the diagnosis of FMF especially after year 2000. <h3>Conclusions</h3> Instead of demographic, clinical and genetic differences, early diagnosis may related with increased patient awareness about the disease. Furthermore, availability of MEFV mutation may influence doctors9 decision making positively for facilitating early diagnosis of FMF and may replace clinical features. But, this may lead to failures in diagnosis in gene-negative FMF cases. <h3>References</h3> Ben-Chetrit, E. M. Levy (1998) Familial Mediterranean fever.Lancet 351:659–64 Livneh, A., P. Langevitz, D. Zemer, N. Zaks, S. Kees, T. Lidar, A. Migdal, S. PadehM. Pras (1997) Criteria for the diagnosis of familial Mediterranean fever.Arthritis Rheum 40:1879–85 <h3>Disclosure of Interest</h3> None declared
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Authors: Jeff Sharman, Sven de Vos, John P. Leonard, Richard R. Furman, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Jaqueline C. Barrientos, Nina D. Wagner-Johnston, Thomas Boyd, Nathan H. Fowler, Leanne Holes, Brian Lannutti, David Johnson, Thomas M. Jahn, Langdon L Miller
Journal: Blood (2011)
FRI0380 IL-6 Receptor Polymorphism in Polymyalgia Rheumatica; Relationship between ASP358ALA (T/G) Polymorphism of The Interleukin 6 Receptor (IL6R) Gene and Susceptibility and Severity of The Disease
Authors: L. Boiardi, P. Macchioni, E. Farnetti, G. Restuccia, L. Pulsatelli, R. Meliconi, C. Salvarani
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In previous study, we found in Polymyalgia rheumatica (PMR) patients a significant correlation between the number of relapses and serum soluble interleukin-6 receptors (sIL-6R) concentrations at baseline and after 1, 3, and 12 months of therapy (1). The Asp358Ala (T/G) polymorphism of the interleukin 6 receptor (IL6R) was related with high levels of ser1um sIL-6R. <h3>Objectives</h3> The Aim of our study was to evaluate the relationship between Asp358Ala (T/G) polymorphism of IL6R gene and susceptibility and severity of the PMR <h3>Methods</h3> We studied 104 patients with pure PMR and 94 healthy controls. Serum levels of s-IL6R were evaluated using highly sensitive, commercial sandwich enzyme-linked immunosorbent assay kits (R&amp;D Systems, Minneapolis, MN) according to the manufacturer9s instructions. The IL6R Asp358Ala polymorphism (rs8192284) were molecularly genotyped <h3>Results</h3> The distribution of allele and genotype frequencies did not differ significantly between PMR patients and healthy controls. Carriers of the Asp358Ala T allele (TT+GT) in PMR patients was 58.7% and in Healthy controls was 60.6% (p=0.78). Homozygosity for the T allele in PMR patients was 16.3% and in healthy control was 12.8% (p=0.48). However the patients and controls with this polymorphism presented higher level of serum s-IL6R. Finally, PMR patients with relapses/recurrences showed more frequently homozygosity for the T allele, but the difference with patients without relapses/recurrences was not statistically significant (p=0.07). <h3>Conclusions</h3> Asp358Ala (T/G) polymorphism of the IL6R was related with high serum levels of s-IL6R; however, no correlation existed between this polymorphism and PMR susceptibily. Moreover, a bordeline correlation existed between TT homozygosity and relapses/recurrences in these patients. <h3>References</h3> Pulsatelli L, Boiardi L, Pignotti E et al. Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse/recurrence risk. Arthritis Rheum. 2008;59:1147–54. <h3>Disclosure of Interest</h3> None declared
In-Depth Quantitative Multiplex Proteomics Reveal Subtype-Specific Differences Among Functionally Validated AML Stem Cell Populations
Authors: Simon Raffel, Jenny Hansson, Carl Herrmann, Christoph Lutz, Eike C. Buss, Christian Thiede, Anne Floercken, Oliver Bischel, Joerg Westermann, Gerhard Ehninger, Anthony D Ho, Roland Eils, Jeroen Krijgsveld, Andreas Trumpp
Journal: Blood (2014)
The Impact of 20q Deletion on Clinical Presentation, Treatment Response and Survival in Patients with Acute Myeloid Leukemia (AML): The University of Texas MD Anderson Cancer Center Experience
Authors: Jad Chahoud, Hagop M. Kantarjian, Farhad Ravandi, Koji Sasaki, Guillermo Garcia-Manero, Jorge E. Cortes, Tapan Kadia, Mark Brandt, Elias Jabbour
Journal: Blood (2015)
BCR-ABL Tyrosine Kinase Inhibitors Interfere with the PI3K/Akt Signalling Pathway and Activate the Microphthalmia-Associated Transcription Factor (MITF) in Human Dendritic Cells
Authors: Daniela Doerfel, Michael Gutknecht, Melanie Märklin, Lothar Kanz, Helmut R. Salih, Frank Gruenebach, Martin R Müller, Susanne M Rittig
Journal: Blood (2014)
The Combination of Arsenic Trioxide and Interferon-Alpha Eradicates Leukemia Initiating Cells in TAX-Driven Murine Adult T Cell Leukemia/Lymphoma.
Authors: Ali Bazarbachi, Hiba El Hajj, Marwan El-Sabban, Hideki Hasegawa, Ghazi Zaatari, Shahrazad Saab, Anne Janin, Rami Mahfouz, Rihab Nasr, Youmna Kfoury, Christophe Nicot, Olivier Hermine, William Hall, Hugues de The
Journal: Blood (2009)